Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D.

J Thromb Haemost. 2007 Dec;5(12):2368-75. Epub 2007 Sep 15.

2.

Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement.

Lassen MR.

Drugs Today (Barc). 2012 Apr;48(4):249-58. doi: 10.1358/dot.2012.48.4.1738052. Review.

PMID:
22536567
3.

Apixaban: an oral direct factor-xa inhibitor.

Jiménez D, Yusen RD, Ramacciotti E.

Adv Ther. 2012 Mar;29(3):187-201. doi: 10.1007/s12325-012-0003-2. Epub 2012 Feb 17. Review.

PMID:
22354465
4.

Apixaban. After hip or knee replacement: LMWH remains the standard treatment.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):201-2, 204. Review.

PMID:
23016247
5.

The role of apixaban for venous and arterial thromboembolic disease.

Prom R, Spinler SA.

Ann Pharmacother. 2011 Oct;45(10):1262-83. doi: 10.1345/aph.1Q119. Epub 2011 Sep 27. Review.

PMID:
21954450
6.

Apixaban: a novel oral inhibitor of factor Xa.

Nutescu E.

Am J Health Syst Pharm. 2012 Jul 1;69(13):1113-26. doi: 10.2146/ajhp110418. Review.

PMID:
22722590
7.

Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.

Martin MT, Nutescu EA.

Curr Med Res Opin. 2011 Nov;27(11):2123-31. doi: 10.1185/03007995.2011.619178. Epub 2011 Sep 23. Review.

PMID:
21942466
8.

Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Deeks ED.

Drugs. 2012 Jun 18;72(9):1271-91. doi: 10.2165/11209020-000000000-00000. Review.

PMID:
22686618
9.

[Apixaban: pharmacology and action profile].

Gassanov N, Caglayan E, Er F.

Dtsch Med Wochenschr. 2012 Jan;137(4):138-41. doi: 10.1055/s-0031-1298816. Epub 2012 Jan 18. Review. German.

PMID:
22259168
10.
11.

Apixaban: a new player in the anticoagulant class.

Agrawal R, Jain P, Dikshit SN.

Curr Drug Targets. 2012 Jun;13(6):863-75. Review.

PMID:
22250655
12.
13.

The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.

Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D, Simon TA, Sutton A.

Clin Appl Thromb Hemost. 2012 Nov;18(6):611-27. doi: 10.1177/1076029612437579. Epub 2012 Mar 2. Review.

PMID:
22387582
14.

Setting a standard for venous thromboembolism prophylaxis.

Turpie AG.

Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S18-23. Review.

PMID:
11715835
15.

Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.

Maniscalco P, Caforio M, Imberti D, Porcellini G, Benedetti R.

Clin Appl Thromb Hemost. 2015 Mar;21(2):115-9. doi: 10.1177/1076029614546328. Epub 2014 Aug 13. Review.

PMID:
25125051
16.

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E.

BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675. Review.

17.

Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.

Turpie AG.

Surg Technol Int. 2004;13:261-7. Review.

PMID:
15744699
18.

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict.

Carreiro J, Ansell J.

Expert Opin Investig Drugs. 2008 Dec;17(12):1937-45. doi: 10.1517/13543780802528625 . Review.

PMID:
19012508
19.
20.

Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.

Yoshida Rde A, Yoshida WB, Maffei FH, El Dib R, Nunes R, Rollo HA.

Ann Vasc Surg. 2013 Apr;27(3):355-69. doi: 10.1016/j.avsg.2012.06.010. Epub 2013 Jan 23. Review.

PMID:
23351997
Items per page

Supplemental Content

Write to the Help Desk